Switch to
More onapp

How to use scorecard? Learn more

Bafna Pharmaceuticals Ltd

BAFNAPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹193 cr, stock is ranked 2,507
Moderate RiskStock is 2.79x as volatile as Nifty
81.501.00 (+1.24%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹193 cr, stock is ranked 2,507
Moderate RiskStock is 2.79x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
483.36
PB RatioPB Ratio
2.39
Dividend YieldDiv. Yield
Sector PESector PE
51.90
Sector PBSector PB
6.61
Sector Div YldSctr Div Yld
0.52%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.

Financial TrendFinancial statements 

202120222023202471.9786.84118.62155.995.835.2211.337.35
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Copy of Newspaper Publication 
Announced OnNov 16, 2024

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication in connection with Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 | Download

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication in connection with Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 | Download

Outcome of Board Meeting 
Announced OnNov 11, 2024

Bafna Pharmaceuticals Limited has informed the Exchange regarding the outcome Board meeting held on November 11, 2024. | Download

Bafna Pharmaceuticals Limited has informed the Exchange regarding the outcome Board meeting held on November 11, 2024. | Download

Cash Dividend 
Ex. DateSep 19, 2013

Final • Div/Share: ₹ 0.6

See all events